Vitiligo
main-banner
Vitiligo
INCB54707-304 Enrolling

Research Trial for Non-Segmental Vitiligo (112 Weeks)


Treatment: Oral Age: 18 Years


Who Can Participate?

Adults (aged ≥ 18 years) with non-segmental vitiligo, may be eligible to participate.

Inclusion Criteria:

  • Clinical diagnosis of non-segmental vitiligo
  • Depigmentation (loss of skin colour) on areas of the face and body
  • Agree to discontinue all agents and procedures used to treat vitiligo, during the study 

What Are The Benefits? 

  • Participants will not be charged for taking part in this trial
  • Regular visits with study doctors who specialize in treating non-segmental vitiligo
  • Will receive either an investigational oral treatment (active study drug) or placebo
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last?

  • 112 weeks (17 clinic visits, plus 6 remote visits)

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Benjamin Barankin

Dermatologist

Dr. Anatoli Freiman

Dermatologist

Dr. Mark Lomaga

Dermatologist

Dr. Charles Lynde

Dermatologist

Dr. Maxwell Sauder

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: July 09, 2024

Official Title

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

ClinicalTrials.gov ID

NCT06113471

Sponsor

Incyte Corporation

Study Description

  • Brief Summary:

    This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

  • Condition or Disease:

    NonSegmental Vitiligo

  • Intervention/Treatment:

    Drug: Povorcitinib Drug: Placebo
  • Phase:

    PHASE3

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL

Inclusion Criteria:

  • Clinical diagnosis of non-segmental vitiligo
  • Depigmentation (loss of skin colour) on areas of the face and body
  • Agree to discontinue all agents and procedures used to treat vitiligo, during the study 

Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Vitiligo

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content